LEVETIRACETAM TEVA ® 250 MG

Land: Israel

Språk: engelsk

Kilde: Ministry of Health

Aktiv ingrediens:

LEVETIRACETAM 250 MG

Tilgjengelig fra:

TEVA PHARMACEUTICAL INDUST.LTD

ATC-kode:

N03AX14

Legemiddelform:

TABLETS

Administreringsrute:

PER OS

Produsert av:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Terapeutisk gruppe:

LEVETIRACETAM

Indikasjoner:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Autorisasjon dato:

2009-09-01